Commonwealth Equity Services
MCRB icon

Commonwealth Equity Services’s Seres Therapeutics MCRB Stock Holding History

Commonwealth Equity Services’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-580
Closed -$8K – 4315
2025
Q1 		$8K Hold
580
– – ﹤0.01% 4158
2024
Q4 		$10K Buy
580
+25
+5% +$406 ﹤0.01% 4070
2024
Q3 		$11K Sell
555
-13
-2% -$264 ﹤0.01% 4025
2024
Q2 		$8K Hold
568
– – ﹤0.01% 4007
2024
Q1 		$9K Buy
+568
New +$12.2K ﹤0.01% 3998
2023
Q4 		– Sell
-552
Closed -$26K – 3973
2023
Q3 		$26K Buy
+552
New +$42.1K ﹤0.01% 3714

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Commonwealth Equity Services's MCRB Position: Q2 2025 in Review

Commonwealth Equity Services sold out of Seres Therapeutics (MCRB) in Q2 2025, closing a stake of 580 shares — an estimated $8K sold.

Commonwealth Equity Services first reported a position in MCRB in Q3 2023 and held it in 6 quarters. The position peaked at $26K in Q3 2023. 33 funds tracked by Wall St. Rank hold MCRB as of Q2 2025.

  • Commonwealth Equity Services reported no remaining Seres Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Commonwealth Equity Services sold 580 Seres Therapeutics shares in Q2 2025, an estimated $8K.
  • Commonwealth Equity Services first reported a position in Seres Therapeutics in Q3 2023 and held it in 6 quarters.
  • Commonwealth Equity Services's Seres Therapeutics position peaked at $26K in Q3 2023.
  • 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2025.

Based on Commonwealth Equity Services's 13F filing for Q2 2025, filed 6 Aug 2025.